31 results about "Prefrontal cortex" patented technology

Methods, apparatuses, and systems for analysis of electromagnetic activity of prefrontal cortex neurons in subjects are provided. The methods, apparatuses, and systems of the present invention can be used as a means to screen for cognitive modulators. They can be used to predict the effects of compounds such as psychostimulants and other drugs on prefrontal cortex-dependent cognition.

System and method for automatically broadcasting voice-based prompt warnings toward an embarkation and / or disembarkation location at which passengers such as students and others may or will be present. The method is multi-model providing voice messages during an approach mode, a stop mode and a standby mode. Recorded human voice messages are employed for the prompt and are the recorded voices of one or more people having voice characteristics generally recognizable by the passengers to an extent effective to supplement the function of the immature prefrontal cortex.

The invention belongs to the technical field of brain science cognition, and particularly relates to a near-infrared spectroscopy detection method of an ambient light modulated brain cognition function. According to the method, functional near-infrared spectroscopy (fNIRS) is utilized, a classical paradigm Stroop of cognitive behavioral psychology is combined, and the influence of ambient light change on the cognitive function of a human brain is explored for a prefrontal cortex (PFC) area with high correlation with the cognitive function of the human brain; The near-infrared spectroscopy detection method comprises the steps of designing an experiment environment; designing psychological Stroop experiment stimulation rules; designing an experiment process; building an experiment system; configuring a detection channel; combining a Stroop psychological test method with the fNIRS for testing; and finally, carrying out fNIRS data processing. Brain activation area images under different illumination conditions are obtained, and brain area channels with significant difference (P is smaller than 0.05) under different illumination conditions are obtained through t test, which proves thatthe channels are activated due to ambient light change.

In DN-DISC1 mice, a mouse model for major mental illnesses, the model that expresses pathological phenotypes relevant to schizophrenia, mood disorders, and addiction simultaneously, the inventors of the present invention found pronounced levels of oxidative stress in the prefrontal cortex, but not in the striatum. These mice also displayed greater amounts of GAPDH-Siah1 binding, a protein-protein interaction that is activated under exposure to oxidative stress. The present inventors investigated the role of oxidative stress in other organ systems. As detailed herein, the inventors found that GAPDH-Siah1 binding was increased in mouse models of cardiac failure. It was also found, that certain novel analogs of deprenyl, significantly inhibited GAPDH-Siah1 binding in cardiac tissue. Thus, with experimental data provided herein, it is clear that this GAPDH-Siah1 binding cascade is a crucial mechanism involved in major mental illness, such as schizophrenia, mood disorders, and addiction, as well as in stress-associated diseases involving other organs where GAPDH is expressed.The present invention provides compounds and composition comprising analogs of deprenyl and their use in the inhibition of nuclear GAPDH-Siah1 binding and the activation of p300 and MEF2. Also provided herein are methods of prevention and treatment of stress induced disorders of the body, including, for example, major mental illness, such as schizophrenia, mood disorders, and addiction, as well as in stress-associated diseases involving other organs, such as cardiac hypertrophy, in vivo, comprising administering to a mammal a therapeutically effective amount of analogs of deprenyl.

A methylphenidate, particularly comprising dex-threo-methylphenidate, administered to a subject for the treatment of gait or limb disturbance secondary to a genetically acquired prefrontal cortex processing disease or condition, wherein the prefrontal cortex processing Diseases or conditions specifically include multiple sclerosis, cerebral palsy, Angelman syndrome, Rett syndrome and fragile X syndrome.

The invention discloses the application of a chemical genetic drug composition in preparing a drug for preventing and treating propofol addiction. The propofol addiction mainly involves two classic addictive behaviors, behavioral sensitization and self-administration. The present invention fully proves that after long-term repeated use of propofol in rats, addictive behavior will be produced, which is mainly caused by the excitation of neurons in the medial prefrontal cortex (mPFC area) of the cortex; Inhibits the hyperexcitable state of mPFC region induced by propofol, thereby inhibiting propofol-addictive behavior in rats. The chemical genetic drug composition provided by the invention has the advantages of good effect, strong controllability and the like, and provides a new therapeutic drug for the treatment, research, development and prevention of propofol addiction.

The invention discloses glycopeptide having the function of resisting depression and a preparation method and application of the glycopeptide. The glycopeptide having the function of resisting depression is from glossy ganoderma, the N-terminal sequence of the glycopeptide is as shown in a sequence 1 in a sequence table, and the glycopeptide has 4 peptide segments as shown in 1-4 in the sequence table. The glycopeptide can reduce the tail suspension fixing time of mice, reduce the swimming dead time of the mice, increase the sucrose preference ratio of depression mice, increase the level of 5-hydroxytryptamine in prefrontal cortex of the depression mice, increase the level of noradrenaline in the prefrontal cortex of the depression mice, increase the expression level of BDNF protein in theprefrontal cortex of the depression mice and reduce the content of corticosterone of the depression mice. The glycopeptide can be used for preventing and / or treating depression.

The invention relates to a human brain health training system which is based on the SAAS (Software as a Service) platform. The system comprises a user interactive interface layer, a business logic service layer and a data access interface, wherein the user interactive interface layer comprises a client which is based on the Web platform or a mobile platform and provides data service; the business logic service layer comprises an account service module, a brain stimulation implementation module, a brain data collection module, an assessment service module, a course service module, a brain index analysis module and a system report service module; and the data access interface comprises a core data interface, a user data interface and a cognitive ability index data interface. The system provided by the invention can improve the cranial nerve circuitry junction in the memory area, is beneficial to the improvement of the memory storage capacity, can further strengthen the capability of the executive function area positioned at the prefrontal cortex, and finally adjusts the advanced function of human body, coordinates all kinds of neural activities of the function, and improves brain advanced functions such as brain health, emotion and the like.

The invention discloses an application of a chemical genetics pharmaceutical composition in preparation of a medicine for preventing and treating propofol addiction. The propofol addiction mainly relates to two classic addiction behaviors of behavior sensitization and self-administration. The invention fully proves that the addiction behaviors are generated after propofol is repeatedly used for along time for a rat, and the addiction behaviors are mainly caused by excitation of neurons of the prefrontal cortex (mPFC region) on the inner side of the cortex; and the mPFC region high excitationstate caused by the propofol can be effectively inhibited by utilizing the chemical genetics pharmaceutical composition, so that the propofol addiction behaviors of the rat is inhibited. The chemicalgenetics pharmaceutical composition provided by the invention has the advantages of good effect, strong controllability and the like, and provides a new therapeutic medicine for treating, researchingand developing and preventing propofol addiction.

The invention relates to the technical field of medicines, in particular to a medicine composition and its application. The pharmaceutical composition provided by the invention comprises: atomoxetine hydrochloride and taurine. The combination of the two can produce a synergistic effect. The present invention finds through experiments that, compared with the administration of atomoxetine hydrochloride alone, the combination of taurine and atomoxetine hydrochloride can more significantly increase the SOD activity and GSH content in the brain tissue of juvenile ADHD model rats, and down-regulate the MDA content (P<0.01), played an anti-oxidation role, increased the expression of DBH and TH in the brain of juvenile ADHD model rats, and up-regulated the expression of Fos protein in the prefrontal cortex of the brain (P<0.01). Compared with single administration, the effect of the pharmaceutical composition is more obvious. Therefore, the pharmaceutical composition of the present invention can be used as a candidate drug for treating ADHD in children.

A deep and repetitive transcranial magnetic stimulation of an individual is performed by applying magnetic pulses at least to a region of the scalp of the individual, the region being at least the bilateral prefrontal cortex, and can include preferably the bilateral prefrontal cortex and can include the insula. A threshold intensity of the magnetic pulses is determined by applying to the individual one or more reference magnetic stimulations, and a reaction of the individual to the reference stimulation is determined. The reaction corresponds to a right thumb movement. A magnetic stimulation is repeatedly applied for at least 80 trains per session for a duration not exceeding 2 seconds each with a time interval between a train application and the next one not less than 20 seconds, wherein the magnetic stimulation has a frequency of at least 18 Hz with an intensity of stimulation at least 120% of the threshold intensity.

The present invention provides methods of preventing and / or reducing risk of neurodegeneration of association cortex, and / or inhibiting or reversing formation of phosphorylated tau or COXIV in the prefrontal cortex of a mammal in need thereof. In certain embodiments, the method comprises administering to the mammal a therapeutically effective amount of an α2A-adrenergic receptor agonist.

The invention discloses use of a human milk oligosaccharide (HMO), or a nutritional composition comprising a human milk oligosaccharide, to enhance executive function in a non-infant, to prevent and / or reduce the risk of sub-optimal executive function in a non-infant, to manage sub-optimal executive functioning in a non-infant, and / or to improve myelination to mature the pre-frontal cortex region of the brain in a non-infant, as well as synthetic compositions of HMOs and packs comprising at least 14 individual daily doses of an effective amount of at least one HMO for such a use.